Predictors of the efficiency of neoadjuvant hormone therapy

Semiglazov V.F.; Pen'kov K.D.; Manikhas A.G.; Paltuev R.M.; Skvortsov V.V.; Raskin G.G.

doi:https://doi.org/

Semiglazov V.F.

FGBU "NII onkologii im. N.N. Petrova"

Pen'kov K.D.

FGBU "NII onkologii im. N.N. Petrova"

Manikhas A.G.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Paltuev R.M.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Skvortsov V.V.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Raskin G.G.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Predictors of the efficiency of neoadjuvant hormone therapy

Authors:

Semiglazov V.F., Pen'kov K.D., Manikhas A.G., Paltuev R.M., Skvortsov V.V., Raskin G.G.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(2): 43‑45

Read: 1295 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Semiglazov VF, Pen'kov KD, Manikhas AG, Paltuev RM, Skvortsov VV, Raskin GG. Predictors of the efficiency of neoadjuvant hormone therapy. P.A. Herzen Journal of Oncology. 2013;2(2):43‑45. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Capsular contracture after reconstructive plastic surgery for breast cancer. P.A. Herzen Journal of Oncology. 2024;(6):78-83

Neoadjuvant drug therapy and oncological outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Oncology. 2025;(1):5-12

Treatment outcomes of stage IIA–IIB breast cancer patients of hormone-positive HER2-negative subtype after neoadjuvant polychemotherapy depending on Ki-67 levels. P.A. Herzen Journal of Oncology. 2025;(2):13-18

NDRG1 protein expression in breast cancer samples, relationship with lymph nodes metastasis. Russian Journal of Archive of Pathology. 2024;(6):36-42

Impact of tumor size on actuarial survival of patients with primary breast sarcoma: a case-control study. Pirogov Russian Journal of Surgery. 2024;(12):38-43

Assessment of risk factors for breast cancer development in women living in the Saratov region. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):100-106

Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in antitumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143

Nottingham Prognostic Index relation to cytokine-producing tumor molecular subtypes in breast cancer. Russian Journal of Preventive Medicine. 2025;(1):63-68

The possibilities of predicting and reducing the risk of breast cancer in women against the background of the use of assisted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):59-64

The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer. Russian Journal of Archive of Pathology. 2025;(2):5-10

Abstract:

This retrospective trial enrolled 440 postmenopausal estrogen and/or progesterone receptor positive (T2N1-2, T3N0-1, T4N0M0) patients who had previously (2001-2011) received neoadjuvant hormone therapy with aromatase inhibitors (anastrozole, letrozole, exemestane, n = 211 or tamoxifen (n = 229). There was a high objective response in both groups at a high level of estrogen receptors. During a 60-month median follow-up, distant metastases were found in 25.5% in the tamoxifen group and in 12% in the aromatase inhibitor group at moderate and high level of cyclin D1.

Keywords:

breast cancer

hormone therapy

aromatase inhibitors

receptor coexpressio

Authors:

Semiglazov V.F.

FGBU "NII onkologii im. N.N. Petrova"

Pen'kov K.D.

FGBU "NII onkologii im. N.N. Petrova"

Manikhas A.G.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Paltuev R.M.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Skvortsov V.V.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Raskin G.G.

SPbGBUZ "Gorodskoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Close metadata

References:

Ring A., Smith I., Ashley S., Fulford L.G., Lakhani S.R. Oestrogen receptor status, pathological complete response and prognosis in patient receiving neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer. 2004; 91 (12): 2012-17.
Colleoni M., Viale G., Zahrieh D., Pruneri G., Gentilini O., Veronesi P. et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 2004; 10 (19): 6622-8.
Colleoni M., Viale G., Zahrieh D., Bottiglieri L., Gelber R., Veronesi P. et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann. Oncol. 2008; 19 (3): 465-72.
Semiglazov V., Kletsel A., Semiglazov V., Zhiltzova E., Ivanov V., Dashyan G. et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER + breast cancer (T2N1-2, T3N0-1, T4N0M0) [abstract]. J. Clin. Oncol.: ASCO Annual Meeting Proceedings. 2005; 23 (16S, Pt 1-2, Suppl.): 530.
Semiglazov V.F., Semiglazov V.V., Dashyan G., Ziltsova E., Ivanov V., Bozhok A. et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007; 110: 244-54.
Johnston S., Pippen J.Jr., Pivot X., Lichinitser M., Sadeghi S., Dieras V. et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009; 27 (33): 5538-46.
Baselga J., Semiglazov V., van Dam P., Manikhas A., Bellet M., Mayordomo J. et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 2009; 27 (16): 2630-7.